A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.
Sorafenib, in combination with conventional transarterial chemoembolization (cTACE), does not significantly improve overall survival (OS) in hepatocellular carcinoma (HCC) patients, relative to sorafenib alone, a recent study has found.
At the recent forum “Improving Access to Affordable Cancer Treatments in Malaysia”, the issue of treatment costs was discussed by panellists from the Ministry of Health (MOH) and pharmaceutical industry representatives.
Long-term results of the POET* trial have suggested that patients with left-sided infective endocarditis (IE) could safely switch from conventional intravenous (IV) antibiotics to oral antibiotics, with oral antibiotics associated with a reduced mortality risk.
Icosapent ethyl – a prescription and highly purified version of the omega-3 fatty acid, eicosapentaenoic acid (EPA) – takes the spotlight in REDUCE-IT* as it markedly reduced the rate of total ischaemic events in individuals with high cardiovascular (CV) risk**.
The fully human monoclonal antibody secukinumab triumphed over ustekinumab once again in patients with moderate-to-severe plaque psoriasis, according to the phase IIIb CLARITY* trial presented at the recent annual meeting of the American Academy of Dermatology (AAD 2019).
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.